Answers are grounded in this paper and cite their sources.
Background: Persons with hemophilia A (HA) and inhibitors undergoing emicizumab prophylaxis require bypassing agents when breakthrough bleeding occurs. Recent studies have demonstrated that either factor (F)IX or FX supplementation can improve coagulation potential of emicizumab-treated persons with HA and inhibitors. Objectives: This study assessed the effect of combined supplementation with FIX and FX on the coagulation potential in emicizumab-treated HA state. Methods: method, emicizumab (3 mg/kg) and human (h)FIX/hFX (100 IU/kg each) were intravenously administered to HA mice (emicizumab-HA mice). Coagulation potentials in these mice with or without additional hFIX/hFX (100 IU/dL each) were assessed by clotting time plus clot formation time (CT + CFT) and blood loss using rotational thromboelastometry and tail-clip assay. Results: Ad|min1| and PeakTh in FVIII-deficient plasmas with emicizumab, FIX, and FX increased in FIX dose dependently. Addition of FIX and FX (100 IU/dL each) to emicizumab-supplemented FVIII-deficient plasma and plasma of emicizumab-treated persons with HA and inhibitor improved both parameters to normal levels. CT+CFT and blood loss in emicizumab-HA mice with additional hFIX/hFX (100 IU/dL each) administration were significantly shorter and decreased than those in emicizumab-HA mice. The thrombotic markers largely did not change. Conclusion: Combined FIX and FX supplementation could enhance coagulation potential in emicizumab-treated persons with HA and inhibitors.
No takes yet. Share an insight, caveat, or question.
Osuna et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: